Journal
NATURE GENETICS
Volume 48, Issue 4, Pages 407-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/ng.3520
Keywords
-
Categories
Funding
- National Cancer Institute [2R01CA120528]
- International Mesothelioma Program at Brigham and Women's Hospital
- Genentech, Inc.
Ask authors/readers for more resources
We analyzed transcriptomes (n = 211), whole exomes (n = 99) and targeted exomes (n = 103) from 216 malignant pleural mesothelioma (MPM) tumors. Using RNA-seq data, we identified four distinct molecular subtypes: sarcomatoid, epithelioid, biphasic-epithelioid (biphasic-E) and biphasic-sarcomatoid (biphasic-S). Through exome analysis, we found BAP1, NF2, TP53, SETD2, DDX3X, ULK2, RYR2, CFAP45, SETDB1 and DDX51 to be significantly mutated (q-score >= 0.8) in MPMs. We identified recurrent mutations in several genes, including SF3B1 (similar to 2%; 4/216) and TRAF7 (similar to 2%; 5/216). SF3B1-mutant samples showed a splicing profile distinct from that of wild-type tumors. TRAF7 alterations occurred primarily in the WD40 domain and were, except in one case, mutually exclusive with NF2 alterations. We found recurrent gene fusions and splice alterations to be frequent mechanisms for inactivation of NF2, BAP1 and SETD2. Through integrated analyses, we identified alterations in Hippo, mTOR, histone methylation, RNA helicase and p53 signaling pathways in MPMs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available